Detalles de la búsqueda
1.
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
Euro Surveill
; 29(8)2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38390651
2.
Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessment.
Vaccine
; 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38834430
3.
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
Influenza Other Respir Viruses
; 18(5): e13294, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38716791
4.
Frequency, Associated Risk Factors, and Characteristics of COVID-19 Among Healthcare Personnel in a Spanish Health Department.
Am J Prev Med
; 59(6): e221-e229, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33220760
Resultados
1 -
4
de 4
1
Próxima >
>>